Royal Bank of Canada
VERV

Royal Bank of Canada’s Verve Therapeutics VERV Stock Holding History

Royal Bank of Canada’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,615
Closed -$176K – 7554
2025
Q2 		$176K Sell
15,615
-63,618
-80% -$363K ﹤0.01% 5255
2025
Q1 		$362K Sell
79,233
-612
-0.8% -$4.1K ﹤0.01% 4253
2024
Q4 		$450K Buy
79,845
+43,331
+119% +$244K ﹤0.01% 4158
2024
Q3 		$176K Buy
36,514
+26,024
+248% +$151K ﹤0.01% 4920
2024
Q2 		$51K Sell
10,490
-7,161
-41% -$45K ﹤0.01% 5653
2024
Q1 		$235K Buy
17,651
+4,200
+31% +$55.7K ﹤0.01% 4556
2023
Q4 		$187K Sell
13,451
-6,429
-32% -$79.7K ﹤0.01% 5161
2023
Q3 		$263K Buy
19,880
+2,801
+16% +$45.1K ﹤0.01% 4558
2023
Q2 		$320K Buy
17,079
+5,856
+52% +$97.5K ﹤0.01% 4322
2023
Q1 		$161K Sell
11,223
-1,300
-10% -$25.5K ﹤0.01% 4802
2022
Q4 		$243K Buy
12,523
+5,237
+72% +$139K ﹤0.01% 4714
2022
Q3 		$250K Buy
7,286
+6,155
+544% +$196K ﹤0.01% 4580
2022
Q2 		$17K Sell
1,131
-1,440
-56% -$22.3K ﹤0.01% 6184
2022
Q1 		$58K Sell
2,571
-4,455
-63% -$127K ﹤0.01% 5995
2021
Q4 		$260K Sell
7,026
-1,834
-21% -$77K ﹤0.01% 5076
2021
Q3 		$416K Buy
8,860
+1,760
+25% +$104K ﹤0.01% 4508
2021
Q2 		$428K Buy
+7,100
New +$295K ﹤0.01% 4426

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Royal Bank of Canada's VERV Position: Q3 2025 in Review

Royal Bank of Canada sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 15,615 shares — an estimated $176K sold.

Royal Bank of Canada first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $450K in Q4 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Royal Bank of Canada reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 15,615 Verve Therapeutics shares in Q3 2025, an estimated $176K.
  • Royal Bank of Canada first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Royal Bank of Canada's Verve Therapeutics position peaked at $450K in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Royal Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.